José Clecildo Barreto Bezerra

José Clecildo Barreto Bezerra

Auto-generated profile, based on publicly available information

José Clecildo Barreto Bezerra

Laboratory of Experimental Pathology, Institute of Tropical Pathology and Public Health, Federal University of Goiás

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
BNBruno Neves
Bruno Neves
RBRodolpho C. Braga
Rodolpho C. Braga
JBJosé C. B. Bezerra
José C. B. Bezerra
PCPedro Cravo
Pedro Cravo
CACarolina Andrade
Carolina Andrade
Morbidity and mortality caused by schistosomiasis are serious public health problems in developing countries. Because praziquantel is the only drug in therapeutic use, the risk of drug resistance is a concern. In the search for new schistosomicidal drugs, we performed a target-based chemogenomics screen of a dataset of 2,114 proteins to identify drugs that are approved for clinical use in humans that may be active against multiple life stages of Schistosoma mansoni. Each of these proteins was treated as a potential drug target, and its amino acid sequence was used to interrogate three databases: Therapeutic Target Database (TTD), DrugBank and STITCH. Predicted drug-target interactions were refined using a combination of approaches, including pairwise alignment, conservation state of functional regions and chemical space analysis. To validate our strategy, several drugs previously shown to be active against Schistosoma species were correctly predicted, such as clonazepam, auranofin, nifedipine, and artesunate. We were also able to identify 115 drugs that have not yet been experimentally tested against schistosomes and that require further assessment. Some examples are aprindine, gentamicin, clotrimazole, tetrabenazine, griseofulvin, and cinnarizine. In conclusion, we have developed a systematic and focused computer-aided approach to propose approved drugs that may warrant testing and/or serve as lead compounds for the design of new drugs against schistosomes. Schistosomiasis is a neglected tropical disease caused by schistosome parasites that affects millions of people worldwide. The current reliance on a single drug (Praziquantel) for treatment and control of the disease calls for the urgent discovery of novel schistosomicidal agents. One approach that can expedite drug discovery is to find new uses for existing approved drugs, a practice known as drug repositioning. Currently, modern drug repositioning strategies entail the search for compounds that act on a specific target, often a protein known or suspected to be required for survival of the parasite. Drug repositioning approaches for schistosomiasis are now greatly facilitated by the availability of comprehensive schistosome genome data in user-friendly databases. Here, we report a drug repositioning computational strategy that involves identification of novel schistosomicidal drug candidates using similarity between schistosome proteins and known drug targets. Researchers can now use the list of predicted drugs as a basis for deciding which potential schistosomicidal candidates can be tested experimentally.

1 November 2008 in Experimental Parasitology
Verified
Journal Article
Closed access
MVMarina Clare Vinaud
Marina Clare Vinaud
CFCirlane Silva Ferreira
Cirlane Silva Ferreira
RJRuy de Souza Lino Junior
Ruy de Souza Lino Junior
JBJosé Clecildo Barreto Bezerra
José Clecildo Barreto Bezerra

1 August 2007 in Experimental Parasitology
Verified
Journal Article
Closed access
MVMarina C. Vinaud
Marina C. Vinaud
RLRuy de Souza Lino
Ruy de Souza Lino
JBJosé Clecildo Barreto Bezerra
José Clecildo Barreto Bezerra

1 August 2002 in Fitoterapia
Verified
Journal Article
Closed access
JBJ.C.B Bezerra
J.C.B Bezerra
ISI.A Silva
I.A Silva
HFH.D Ferreira
H.D Ferreira
PFP.H Ferri
P.H Ferri
SSS.C Santos
S.C Santos

1 February 2019 in Chemosphere
Verified
Journal Article
Closed access
AMAmanda de Oliveira Melo
Amanda de Oliveira Melo
DSDaniela Braz dos Santos
Daniela Braz dos Santos
LSLuciana Damacena Silva
Luciana Damacena Silva
Thiago Lopes RochaThiago Lopes Rocha
Thiago Lopes Rocha
JBJosé Clecildo Barreto Bezerra
José Clecildo Barreto Bezerra

1 November 1999 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
JBJosé Clecildo Barreto Bezerra
José Clecildo Barreto Bezerra
AKAndreas Kemper
Andreas Kemper
WBWilhelm Becker
Wilhelm Becker
Using high performance liquid chromatography (HPLC) analysis it was possible to determine simultaneously the concentration of organic acids (pyruvate, lactate, succinate, fumarate, malate, acetate, propionate, acetoacetate, and ß-hydroxybutyrate) in the digestive gland and the extracellular concentration of these same acids in the hemolymph of estivating Biomphalaria glabrata, the intermediate host of Schistosoma mansoni. After a 7 day period of estivation, there was a significant increase in the tissue levels of lactate, succinate, malate and acetate compared to non-estivating snails. After 14 days of estivation, the levels of lactate and acetate were also significantly elevated. The hemolymph concentrations of pyruvate and acetate increased significantly after 7 days and acetate concentrations continued to be significantly increased up to 14 days of estivation. The other organic acids studied, such as ketone body acetoacetate and ß-hydroxybutyrate or the volatile acid propionate, did not accumulate. Their tissue concentrations, however, increased on the 7th day of estivation and reached normal levels within two weeks of estivation for some of them. One should take into consideration how the reduction in metabolism can be handled under aerobic conditions, and what role anaerobic pathways may play in both energy formation and redox balance processes.